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Introduction
Pursuant to 24-A M.R.S.A. §4302(5) the Superintendent of Insurance must report annually to the
Joint Standing Committee on Insurance and Financial Services on information provided by
carriers related to claims made for the treatment of Lyme disease and other Tick Borne illnesses.
This report covers calendar year 2009 and contains information related to people who have
individual health insurance policies, those covered under fully insured group health insurance
plans, and those enrolled in the Dirigo Health Plan. It does not include Mainecare, Medicare,
government plans (except the State of Maine Employees Health Plan) or companies that selfinsure. Included within the report are: the number of claims made for the treatment of Lyme
disease and other Tick Borne illnesses; the total dollar amounts of those claims; the number of
claim denials and reasons for those denials; the number and outcome of internal appeals; and the
number of external appeals related to the treatment of Lyme disease and other Tick Borne
illnesses.
The Maine Center for Disease Control and Prevention has identified five kinds of reported Tick
Borne diseases in Maine: Lyme Disease, Babesiosis, Ehrlichiosis (Anaplasmosis), Rocky
Mountain Spotted Fever, and Powassan Virus. Licensed health carriers are required to report to
the Bureau of Insurance claims for all five Tick Borne illnesses. The data include only claims
for the treatment of tick-borne illnesses. They do not include claims for the diagnosis of tickborne illnesses such as laboratory and imaging services.
This data collection requirement was enacted in 2007. The Bureau of Insurance developed an
online report form for all licensed health carriers to enter data regarding Tick Borne disease
treatment claims for all insured Maine residents, whether the carrier’s information is for
enrollees in self-funded or fully insured plans. This was the second year that Tick Borne disease
data was collected. A total of 435 of 443 licensed health carriers responded for a response rate
of 98.2%. Although this response rate is very high and provides a statistically valid sample, the
Bureau is striving to get full compliance with the reporting requirements of the law. Notice has
been sent to all companies that failed to respond with data for 2009 informing them that failure
to respond in future years will result in referral to the Legal Division.
The number of claims for Tick Borne disease and the number of treatments for Lyme disease
should not be confused with the number of actual cases of these diseases because an individual
with these diseases can have many claims filed over the course of their treatment. The results
presented in Table I and Table II cannot be directly compared. There may be several reasons for
this including: multiple claims submitted for treatment of a single case of Lyme disease due to
multiple office visits; companies that could not connect claims to prescriptions; and companies
that reported office visits in Table I but were not certain whether there was Other Treatment in
Table II. In addition, the number of reasons for denied Tick Borne disease claims in Table III
cannot be compared to the number of denials in Table I because there can be more than one
reason for denial of a claim.

Page 1

Several revisions to the reporting form will be made for next year to improve the data to be
reported. These revisions include:
•
•
•

Adding a category for pending cases, since Tables I and II of the existing form ask for
claims submitted, claims paid and claims denied. The number of cases submitted does
not always equal those paid plus denied because some cases are pending;
Adding a new category “Single Course of Treatment over 8 Weeks” to differentiate a
single course of treatment from multiple courses of treatment that total more than 8
weeks; and
Splitting the category “Not Medically Necessary (Including
Experimental/Investigational)” into two categories: “Not Medically Necessary” and
“Experimental/Investigational”.

Tick Borne Disease Claims by Category
Table 1 shows the number of claims submitted, paid and denied by Category of Tick Borne
disease. The reported data include only claims made for the treatment of Tick Borne disease in
the previous calendar year for covered individuals in Maine. This excludes laboratory, imaging
and other claims related to diagnosing Tick Borne diseases. Five categories of Tick Borne
diseases are listed based upon the International Classification of Diseases (ICD-9 codes).
The figures represent the number of claims reported and not the number of enrollees with Tick
Borne disease. For example, one enrollee may have 10 claims within the calendar year relating
to a diagnosis of Lyme disease. The Percentage of Claims Paid column is calculated by dividing
the number of claims paid by category by the number of claims submitted for that category.
The company reporting the largest number of claims (10,700) indicated that they included
presumptive diagnoses and stated that there is no way to separate presumptive diagnoses from
patients with positive cultures.
Table 1. Tick Borne Disease Claims by Category, 2009
Category
Total Number of Claims:
Total
Dollar
Amount
Paid
Submitted
Paid
Denied
Lyme
Babesiosis
Ehrlichiosis (Anaplasmosis)
Rocky Mountain Spotted Fever
Powassan Virus
Totals:

14,807
231
116
15
0
15,169

12,744
133
114
13
0
13,004
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2,057
98
2
2
0
2,159

$1,559,030
$49,484
$53,630
$3,069
$0
$1,665,213

Percentag
e of
Claims
Paid
86%
58%
98%
87%
-86%

Lyme Disease Claims by Treatment Type
Table 2 shows the number of Lyme disease claims by the Type of Treatment provided for those
claims. The reported data include only claims made for the treatment of Tick Borne disease in
the previous calendar year for covered individuals in Maine. This excludes laboratory, imaging
and other claims related to diagnosing Tick Borne diseases. Claims for antibiotic treatment by
any means of administration are counted. If an enrollee submitted claims for an antibiotic
treatment on several different occasions during the calendar year, the combined length of time
that antibiotic was taken is used for the purpose of determining if the treatment was for 8 weeks
or less or for more than 8 weeks. The Other Treatment types may include non-antibiotic
therapies administered for treatment of Lyme disease—including physical therapy, acupuncture,
behavioral health, osteopathic manipulation, or other prescription medications. The Percentage
of Claims Paid column is calculated by dividing the number of claims paid by treatment type by
the number of claims submitted for that treatment type.
It is possible for information about one enrollee to be entered in more than one category. For
example, an enrollee could have paid claims for some antibiotics for 8 weeks or less during the
calendar year. That same enrollee could have a different antibiotic for 8 weeks or less be denied
and additionally have a prescription for more than 8 weeks be paid. The Bureau will add a new
category “Single Course of Treatment over 8 Weeks” to the report form in order to clarify this
issue in the future. Therefore, it may be acceptable to enter data for the same enrollee in more
than one place.
We caution against comparing the reported data in Table 2 to the reported data in Table 1. The
data in Table 2 under-represents the number of Lyme disease claims by treatment type. Based
upon follow-up questions related to the reported data, the Bureau determined that there are
several possible reasons why the numbers are under-represented. These reasons include: for
some insurance companies the data was unavailable; the insurer could not determine the
treatment types for their members; the insurer does not collect the diagnosis at the “point of sale”
of prescriptions or other treatment; the data could only be reported for individual cases and not
the total number of claims; the insurer does not issue prescription coverage in Maine; or medical
claims are stored on separate platforms from pharmacy claims and the two are not tied together.
These discrepancies were identified when Bureau staff reviewed data from the previous year,
and sought clarification from the insurance carriers. After extensive interaction with several
companies, it was determined that discrepancies exist among the companies as to what is being
reported. To address this and improve data for 2011, the Bureau will be providing more
detailed information/data request to all filing companies.
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Table 2. Lyme Disease Claims by Treatment Type
Treatment Type
Total Number of Claims:
Total Dollar
Amount
Paid
Submitted
Paid
Denied
Antibiotic Treatment,
8 weeks or less
Antibiotic Treatment,
more than 8 weeks
Other Treatment
Totals:

Percent
of Claims
Paid

1,691

1,090

600

$179,089

64%

204

124

80

$35,813

61%

233
2,128

213
1,427

15
695

$36,555
$251,457

91%
67%

Reasons for Denied Tick Borne Disease Claims
Table 3 provides the reasons given for denials of payment related to any treatment for Tick
Borne diseases. A claim may have multiple reasons for denial. Nearly two-thirds of the reasons
for denial were listed as other (not among those specifically listed on the report). More than
1,000 of those other reasons came from one insurance carrier. Other reasons for denial provided
by insurance carriers include: duplicate claims; lack of referral; a mismatched membership
number or social security number was provided; the person had other coverage and the primary
payer paid in full; Medicare provided full coverage; the service was provided prior to effective
date; payment was included in the allowance for another service; the provider name was missing;
the claim was submitted to the prescription drug carrier; and a variety of reasons related to
internal process which may have been reprocessed and approved at a later date. Two carriers
(who are in the same insurance group and under common control) reported that their pharmacy
claims are on a different platform and are not tied to medical claims, so the specific reasons for
denial were not known.

Table 3. Reasons for Denied Tick Borne Disease Claims, 2009
Reasons for Denial
Number of
Denied Claims
Other Reasons for Denial
1,372
More Information Requested/Not Received
171
Coverage Terminated
170
Not a Covered Benefit
116
Not Medically Necessary (Including Experimental/Investigational)
102
Incorrect Coding
79
Non-Participating Provider
31
Maximum Benefits Exceeded
15
No Pre-Authorization
9
Pre-Existing Condition Exclusion
0
Total:
2,065
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Appeals/Reconsiderations and External Reviews for All Tick Borne Diseases
Table 4 provides the number of appeals and reconsiderations that were conducted by the
insurance companies reporting data to the Bureau of Insurance. The Bureau had no requests for
an independent external review relating to Lyme disease in 2009.

Table 4. Number of Appeals/Reconsiderations and External Reviews for
All Tick Borne Diseases, 2009
Upheld
Overturned
Total
Appeals/Reconsideration (Internal)
5
5
10
Independent External Reviews
0
0
0
(Conducted by the Insurer,
not the Bureau of Insurance)
Total:
5
5
10
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